RSCM
RLAY icon

Rock Springs Capital Management’s Relay Therapeutics RLAY Stock Holding History

Rock Springs Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-673,966
Closed -$7.42M – 116
2023
Q4 		$7.42M Hold
673,966
– – 0.18% 77
2023
Q3 		$5.67M Hold
673,966
– – 0.15% 83
2023
Q2 		$8.47M Hold
673,966
– – 0.2% 81
2023
Q1 		$11.1M Hold
673,966
– – 0.26% 75
2022
Q4 		$10.1M Buy
673,966
+55,699
+9% +$1.07M 0.24% 72
2022
Q3 		$13.8M Hold
618,267
– – 0.36% 67
2022
Q2 		$10.4M Buy
618,267
+16,600
+3% +$356K 0.3% 76
2022
Q1 		$18M Buy
601,667
+3,900
+0.7% +$94.6K 0.45% 62
2021
Q4 		$18.4M Buy
597,767
+128,207
+27% +$4.05M 0.42% 70
2021
Q3 		$14.8M Buy
469,560
+19,302
+4% +$650K 0.31% 84
2021
Q2 		$16.5M Buy
450,258
+198,131
+79% +$6.53M 0.33% 88
2021
Q1 		$8.72M Sell
252,127
-159,873
-39% -$6.94M 0.19% 121
2020
Q4 		$17.1M Sell
412,000
-1,674
-0.4% -$75.7K 0.36% 86
2020
Q3 		$17.6M Buy
+413,674
New +$15.8M 0.45% 75

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Rock Springs Capital Management's RLAY Position: Q1 2024 in Review

Rock Springs Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2024, closing a stake of 673,966 shares — an estimated $7.42M sold.

Rock Springs Capital Management first reported a position in RLAY in Q3 2020 and held it in 14 quarters. The position peaked at $18.4M in Q4 2021. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

  • Rock Springs Capital Management reported no remaining Relay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Rock Springs Capital Management sold 673,966 Relay Therapeutics shares in Q1 2024, an estimated $7.42M.
  • Rock Springs Capital Management first reported a position in Relay Therapeutics in Q3 2020 and held it in 14 quarters.
  • Rock Springs Capital Management's Relay Therapeutics position peaked at $18.4M in Q4 2021.
  • 189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.